ReviewAntibiotics (Basel, Switzerland)2022
Application of Artificial Intelligence in Combating High Antimicrobial Resistance Rates.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Artificial Intelligence in Infectious Disease Care: Selected Applications in Tuberculosis, Sepsis, and Antimicrobial Stewardship.Diagnostics (Basel, Switzerland) · 2026Review
- Dual dimensions of artificial intelligence use among medical academia: related knowledge, attitudes and ethical concerns, a national survey, 2025.Scientific reports · 2026Article
- Characterization of novel phage Henuyfy11N: a potential therapeutic agent against extended-spectrum β-lactamase (ESBL)-producingMicrobiology spectrum · 2026Article
- Artificial intelligence in microbiology: implications for metagenomics, diagnostics, and AMR surveillance.Biomedical engineering online · 2026Review
- Performance of predictive AI-based clinical decision support systems across clinical domains: A systematic review and meta-analysis.PLOS digital health · 2026Article
- Artificial Intelligence as a Catalyst for Antimicrobial Discovery: From Predictive Models to De Novo Design.Microorganisms · 2026Review
- Leveraging Artificial Intelligence to Advance Bioinformatics in Africa: Opportunities, Challenges, and Ethical Considerations in Combating Antimicrobial Resistance.Bioinformatics and biology insights · 2026Article
- Leveraging artificial intelligence for One Health: opportunities and challenges in tackling antimicrobial resistance - scoping review.One health outlook · 2025Article
- Artificial intelligence-enhanced biosurveillance for antimicrobial resistance in sub-Saharan Africa.International health · 2025Review
- Advancing AMR Surveillance: Confluence of One Health and Big Data Integration : Converging One Health and Big Data for AMR.EcoHealth · 2025Review
- Mitigating antimicrobial resistance by innovative solutions in AI (MARISA): a modified James Lind Alliance analysis.npj antimicrobials and resistance · 2025Article
- Artificial intelligence in Combating Antimicrobial Resistance.Archives of Razi Institute · 2025Review
- Artificial intelligence in drug resistance management.3 Biotech · 2025Review
- The Introduction of the Global Traditional, Complementary, and Integrative Healthcare (TCIH) Research Agenda on Antimicrobial Resistance and Its Added Value to the WHO and the WHO/FAO/UNEP/WOAH 2023 Research Agendas on Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Article
- Challenges and applications of artificial intelligence in infectious diseases and antimicrobial resistance.npj antimicrobials and resistance · 2025Review
- Antibiotic self-medication in Otuke District, Northern Uganda: Prevalence and associated factors.PloS one · 2025Article
- Psychometric assessment of the Persian translated version of the "medical artificial intlligence readiness scale for medical students".PloS one · 2025Article
- Exploring the Potentials of Artificial Intelligence in Sepsis Management in the Intensive Care Unit.Critical care research and practice · 2025Review
- Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.Le infezioni in medicina · 2025Article
- Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is a branch of science and engineering that focuses on the computational understanding of intelligent behavior. Many human professions, including clinical diagnosis and prognosis, are greatly useful from AI. Antimicrobial resistance (AMR) is among the most critical challenges facing Pakistan and the rest of the world. The rising incidence of AMR has become a significant issue, and authorities must take measures to combat the overuse and incorrect use of antibiotics in order to combat rising resistance rates. The widespread use of antibiotics in clinical practice has not only resulted in drug resistance but has also increased the threat of super-resistant bacteria emergence. As AMR rises, clinicians find it more difficult to treat many bacterial infections in a timely manner, and therapy becomes prohibitively costly for patients. To combat the rise in AMR rates, it is critical to implement an institutional antibiotic stewardship program that monitors correct antibiotic use, controls antibiotics, and generates antibiograms. Furthermore, these types of tools may aid in the treatment of patients in the event of a medical emergency in which a physician is unable to wait for bacterial culture results. AI's applications in healthcare might be unlimited, reducing the time it takes to discover new antimicrobial drugs, improving diagnostic and treatment accuracy, and lowering expenses at the same time. The majority of suggested AI solutions for AMR are meant to supplement rather than replace a doctor's prescription or opinion, but rather to serve as a valuable tool for making their work easier. When it comes to infectious diseases, AI has the potential to be a game-changer in the battle against antibiotic resistance. Finally, when selecting antibiotic therapy for infections, data from local antibiotic stewardship programs are critical to ensuring that these bacteria are treated quickly and effectively. Furthermore, organizations such as the World Health Organization (WHO) have underlined the necessity of selecting the appropriate antibiotic and treating for the shortest time feasible to minimize the spread of resistant and invasive resistant bacterial strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.